Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma

References

• Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA. 1982;79(6):2031–2035.
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol. 2012;3:322.
   PubMed Web of Science ®Google Scholar
• Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116(8):1211–1219.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol. 2002;76:240–245.
   PubMed Web of Science ®Google Scholar
• Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60(12):1373–1377.
   PubMed Web of Science ®Google Scholar
• Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005;24(39):6047–6057.
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010 Sep 20;28(27):4177–4183.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Karube K, Kowano R, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis. Int J Oncol. 2004;25(3):605–613.
   PubMed Web of Science ®Google Scholar
• Sekine M, Kubuki Y, Kameda T, et al. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice. Eur J Haematol. 2017;98:501–507.
   PubMed Web of Science ®Google Scholar
• Ishida T, Iida S, Akatsuka Y, et al. The CC chemokine receptor 4 as a novel specific moecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res. 2004;10(22):7529–7539.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466–3473.
   PubMed Web of Science ®Google Scholar
• Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulator T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sezary syndrome. Clin Cancer Res. 2015;21(2):274–285.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28(9):1591–1598.
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30(8):837–842.
   PubMed Web of Science ®Google Scholar
• Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169(5):672–682.
   PubMed Web of Science ®Google Scholar
• Phillips AA, Fields P, Hermine O, et al. A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator’s choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL). J Clin Oncol. 2016; 34(suppl; abstr 7501)
   Google Scholar
• Duvic M, Pinter-Brown L, Foss F, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125(12):1883–1889.
   PubMed Web of Science ®Google Scholar
• Ureshino H, Shindo T, Nishikawa H, et al. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016 [cited 2016 May 23];4:644–649.
   PubMed Web of Science ®Google Scholar
• Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–1163.
   PubMed Web of Science ®Google Scholar
• Ishitsuka K, Murahashi M, Katsuya H, et al. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. Int J Hematol. 2015;102(4):493–497.
   PubMed Web of Science ®Google Scholar
• Morichika K, Tomoyose T, Hanashiro T, et al. Recurrence of psoriasis vulgaris accompanied by treatment with C-C chemokine receptor type 4 (CCR4) antibody (mogamulizumab) therapies in a patient with adult t cell leukemia/lymphoma: insight into auto inflammatory diseases. Intern Med. 2016;55(10):1345–1349.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Fujiwara H, Ochi F, et al. Development of engineered T cells expressing a chimeric CD16-CD3ζ receptor to improve the clinical efficacy of mogamulizumab therapy against adult T cell leukemia. Clin Cancer Res. 2016 [cited 2016 Apr 18];22:4405–4416.
   PubMed Web of Science ®Google Scholar
• Takasaki Y, Iwanaga M, Imaizumi Y, et al. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood. 2010 Jun 3;115(22):4337–4343.
   PubMed Web of Science ®Google Scholar
• Tsukasaki K, Utsunomiya A, Fukuda H, et al. Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25(34):5458–5464.
   PubMed Web of Science ®Google Scholar
• Subramaniam J, Whiteside G, Mckeage K. et al. Mogamulizumab: first global approval. Drugs. 2012;72(9):1293–1298.
   PubMed Web of Science ®Google Scholar
• Mogamulizumab. ClinicalTrials.gov. U.S. Bethesda (MD): National Library of Medicine (US); 2016. Available from: https://clinicaltrials.gov/ct2/results?term=mogamulizumab
   Google Scholar